Author

A. Lanzavecchia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6 Microbiology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Organism:human· 7 Research Focus:host-pathogen & immune response· 6 Research Focus:cell type annotation· 4 Assay:proteomics· 4 Research Focus:differential expression· 3 Research Focus:cell-cell communication· 2 Assay:CITE-seq· 1

Frequent Co-Authors

A. C. Walls· 6 shared D. Corti· 6 shared D. Veesler· 5 shared A. Ceschi· 4 shared J. E. Bowen· 4 shared M. A. Tortorici· 4 shared P. Ferrari· 4 shared Y.-J. Park· 4 shared

Activity by Year

2020-2022 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

A. C. Walls

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape

R. Marzi, J. Bassi, C. Silacci-Fregni, I. Bartha, F. Muoio, K. Culap, N. Sprugasci, G. Lombardo, C. Saliba, E. Cameroni, A. Cassotta, J. S. Low, A. C. Walls, M. McCallum, M. A. Tortorici, , L. Piccoli

The paper examines the kinetics, avidity, and cross-reactivity of SARS-CoV-2-specific memory B cells and antibodies in infected and vaccinated individuals over 16 months, finding that MBC maturation enhances resilience to viral escape.

bioRxiv · Sep 30, 2022Immunology

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

Y.-J. Park, D. Pinto, A. C. Walls, Z. Liu, A. De Marco, F. Benigni, F. Zatta, C. Silacci-Fregni, J. Bassi, K. R. Sprouse, A. Addetia, J. E. Bowen, C. Stewart, M. Giurdanella, C. Saliba, , Piccoli

This study shows that hybrid immunity and vaccine boosters provide potent neutralizing activity against Omicron BA.1 and BA.2, while breakthrough infections induce nasal mucosal neutralization and identify an ultrapotent pan-variant antibody.

bioRxiv · May 8, 2022Immunology

ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies

J. S. Low, J. Jerak, M. A. Tortorici, M. McCallum, D. Pinto, A. Cassotta, M. Foglierini, F. Mele, R. Abdelnabi, B. Weynand, J. Noack, M. Montiel-Ruiz, S. Bianchi, F. Benigni, N. Sprugasci, , F. Sallusto

The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.

bioRxiv · Mar 30, 2022Immunology

Structure, receptor recognition and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein

M. A. Tortorici, A. C. Walls, A. Joshi, Y.-J. Park, R. T. Eguia, T. Stevens-Ayers, M. J. Boeckh, A. Talenti, A. Lanzavecchia, D. Corti, J. D. Bloom, D. Veesler

The paper determines the structure of the CCoV-HuPn-2018 spike glycoprotein, identifies its receptor, and shows cross-neutralizing antibodies against related coronaviruses.

bioRxiv · Oct 25, 2021Microbiology

Extremely potent human monoclonal antibodies for the prophylaxis and therapy of Tetanus

M. Pirazzini, A. Grinzato, D. Corti, S. Barbieri, O. Leka, F. Vallese, M. Tonellato, C. Silacci Fregni, L. Piccoli, E. Kandiah, G. Schiavo, G. Zanotti, A. Lanzavecchia, C. Montecucco

This study identifies two human monoclonal antibodies with high neutralizing activity against tetanus neurotoxin, showing potential for both prophylaxis and therapy.

bioRxiv · May 24, 2021Pathology

A rationally designed oral vaccine induces Immunoglobulin A in the murine gut that directs the evolution of attenuated Salmonella variants

M. Diard, E. Bakkeren, D. Hoces, V. Lentsch, M. Arnoldini, F. Boehi, K. Schumann-Moor, J. Adamcik, L. Piccoli, A. Lanzavecchia, B. Stadtmueller, N. Donohue, M. Vanderwoude, P. Viollier, L. Falquet, , E. Slack

This paper shows that an oral vaccine inducing IgA in mice can direct Salmonella to evolve into less virulent variants with shorter O-antigens.

bioRxiv · May 13, 2021Immunology

Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies

F. A. Lempp, L. Soriaga, M. Montiel-Ruiz, F. Benigni, J. Noack, Y.-J. Park, S. Bianchi, A. C. Walls, J. E. Bowen, J. Zhou, H. Kaiser, M. Agostini, M. Meury, E. Dellota, S. Jaconi, , D. Corti

This study identifies membrane lectins that enhance SARS-CoV-2 infection and show how different antibodies neutralize infection through distinct mechanisms.

bioRxiv · Apr 3, 2021 · PreprintMicrobiology

Clonal dissection of immunodominance and cross-reactivity of the CD4+ T cell response to SARS-CoV-2

J. S. Low, D. Vaqueirinho, F. Mele, M. Foglierini, M. Perotti, D. Jarrossay, S. Jovic, T. Terrot, A. Franzetti Pellanda, M. Biggiogero, C. Garzoni, P. Ferrari, A. Ceschi, A. Lanzavecchia, A. Cassotta, F. Sallusto

The paper identifies immunodominant and cross-reactive CD4+ T cell epitopes in SARS-CoV-2, showing their recognition in 93% of patients and potential for vaccine design.

bioRxiv · Mar 23, 2021Immunology

Structural and functional analysis of a potent sarbecovirus neutralizing antibody

D. Pinto, Y.-J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J. B. Case, , D. Corti

This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.

bioRxiv · Apr 7, 2020Immunology